LegoChem Bio’s Phase II clinical trial of ‘Super Antibody’ designated for accelerated approval by FDA

LegoChem Biosciences(LegoChem Bio) officially announced that Delpazloid(LCB01-0371), a Phase II clinical trial pipeline, was designated as a medicine for the Fast Track process by the U.S. Food and Drug Administration(FDA).

Delpazolid, an antibody developed by LegoChem Bio on its own, has been on a Korean clinical trial with an oral indication for the treatment of multidrug-resistant tuberculo...